How to Calculate GLP-1 Cardiovascular Benefit

What is GLP-1 Cardiovascular Benefit?

The GLP-1 Cardiovascular Benefit Calculator estimates the reduction in major adverse cardiovascular events (MACE) risk based on data from the landmark SELECT trial of semaglutide 2.4 mg. It calculates your personalized MACE risk reduction based on age, cardiovascular history, and GLP-1 treatment duration.

Formula

Reduced MACE Risk = Baseline MACE Risk × (1 - Hazard Ratio Reduction)

MACE₀: Baseline MACE Risk (%/year) — Annual risk of major adverse cardiovascular events without GLP-1 therapy
HR: Hazard Ratio (ratio) — Relative risk from SELECT trial (0.80 = 20% relative reduction)
ARR: Absolute Risk Reduction (%/year) — Annual absolute decrease in MACE risk
NNT: Number Needed to Treat (patients) — Number of patients treated to prevent one MACE event

Step-by-Step Guide

1Enter your age, cardiovascular risk factors, and history of heart attack or stroke
2Select your GLP-1 medication and dose
3The calculator estimates your baseline annual MACE risk and the expected reduction from GLP-1 therapy
4View the number needed to treat (NNT) and absolute risk reduction for your profile

Worked Examples

Input

Age 60, history of MI, BMI 34, on semaglutide 2.4 mg

Result

Baseline annual MACE risk: ~4.5%. With semaglutide (HR 0.80 from SELECT): reduced to ~3.6%. Absolute risk reduction: 0.9%/year. NNT over 3.3 years: ~15.

Input

Age 50, no prior CV events, overweight with hypertension

Result

Baseline annual MACE risk: ~1.5%. With semaglutide: reduced to ~1.2%. Absolute risk reduction: 0.3%/year. NNT much higher — benefit is proportional to baseline risk.

Common Mistakes to Avoid

✕Applying SELECT trial results to patients without established cardiovascular disease — the trial enrolled patients with prior CV events or high CV risk
✕Confusing relative risk reduction (20%) with absolute risk reduction (which depends on baseline risk)
✕Assuming all GLP-1 medications have proven cardiovascular benefit — only semaglutide has completed a CV outcomes trial in obesity

Frequently Asked Questions

Does Ozempic or Wegovy reduce heart attack risk?

Yes. The SELECT trial (2023) demonstrated that semaglutide 2.4 mg reduced MACE (heart attack, stroke, cardiovascular death) by 20% compared to placebo in overweight/obese adults with prior cardiovascular disease. This was the first obesity medication to show a direct cardiovascular benefit.

Do I need to have had a heart attack to benefit from the cardiovascular protection?

The SELECT trial enrolled patients with established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease) plus BMI ≥ 27. While the cardiovascular benefit is proven in this population, trials in lower-risk populations are ongoing.

Ready to calculate? Try the free GLP-1 Cardiovascular Benefit Calculator

Try it yourself →